Pancreatic Cancer

Expert insights on pancreatic cancer, focusing on evolving treatment strategies and clinical decision-making across disease stages.

Daraxonrasib and the Future of RAS Inhibitors in Pancreatic Cancer

Antonella Cammarota, PhD, Michael May, MD

Managing Toxicity and Expanding RAS Therapy in Pancreatic Cancer

Andrew H. Ko, MD, Eileen O'Reilly, MD, Shubham Pant, MD, MBBS, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Doubling Survival: The Clinical Impact of RASolute 302

Andrew H. Ko, MD, Eileen O'Reilly, MD, Shubham Pant, MD, MBBS, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

From Drug Design to Phase 3 Success in RAS-Driven Disease

Andrew H. Ko, MD, Eileen O'Reilly, MD, Shubham Pant, MD, MBBS, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA

Daraxonrasib Delivers Breakthrough Survival Gains in Pancreatic Cancer

Andrew H. Ko, MD, Eileen O'Reilly, MD, Shubham Pant, MD, MBBS, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Clinical Insights: Impact of RASolute 302 on Clinical Practice in Previously Treated Metastatic PDAC

Andrew H. Ko, MD, Shubham Pant, MD, MBBS, Eileen O'Reilly, MD, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Treatment Considerations and Safety Updates in Metastatic Pancreatic Adenocarcinoma

Rahul Gosain, MD, MBA, Rohit Gosain, MD

Advances in Pancreatic and Biliary Tract Cancers at ASCO GI 2026: Expert Insights

Anupriya Singhal, MD, PhD

Pancreatic Cancer Highlights From ASCO GI 2026

Fiyinfolu Balogun, MD, PhD, Angelo Pirozzi, MD

Optimal Frontline Treatment in Metastatic Pancreatic Cancer

Raji Shameem, MD, Rohit Gosain, MD

Molecular Profiling Expands Treatment Options in Pancreatic and Biliary Tract Cancers

Dina Ioffe, MD, Shubham Pant, MD, MBBS

Pancreatic Cancer in 2025: Nearing an Inflection Point

Udhayvir Singh Grewal, MD

Latest GI Cancer Trends From ASCO 2025: Molecular Testing, IO Strategies & Targeted Therapy

Seyi Abidoye, MBBS, Lisa Liu, MD

Managing Toxicities of FOLFIRINOX and Nab-Paclitaxel Plus Gemcitabine

Midhun Malla, MD, Rachna Shroff, MD, MS, FASCO